Capital IdeasTM

Investment insights from Capital Group

Categories
ヘルスケア
Health care: a sector under the weather?
Andy Budden
Investment Director
John Lamb
Investment Specialist

2023 was the worst year for health care stocks on a relative basis since 1999, underperforming the broad global equity market by 20%. Excluding Novo Nordisk and Eli Lilly − two large and notable outliers whose successful diabetes/obesity drug franchises drove extraordinary share price returns last year − the sector would have underperformed even more, by 24%.


Relative performance of MSCI World Health Care vs MSCI World index (in US$ terms)

Relative performance of MSCI World Health Care vs MSCI World index (in US$ terms)

Past results are no guarantee of future results
Data by calendar year from 1 January 1995 to 31 December 2023. Based on the difference in the net total return of each index, calculated on an arithmetic basis. Source: Datastream.

As is often the case, there is no single reason contributing to the relative weakness within the healthcare sector recently and this piece looks at a few candidates, including the risk-on environment in 2023, the Inflation Reduction Act (IRA) in the US and M&A risk.


With the US presidential elections now less than a year away, this is also weighing on investor sentiment across the health care sector. The US spends the most per capita of any country on health care, making drug pricing a low- hanging political fruit for both sides of the spectrum on which to appear tough in order to win voters. But while the theory is clear, is there any evidence supporting the conventional wisdom that health care stocks should suffer during an election year?


While the sector can be exposed to political noise, there are plenty of reasons for optimism as we enter a ‘golden era’ of health care innovation. As ever, deep fundamental research and a long-term perspective are essential for uncovering potential durable investment opportunities.



Andy Budden is an Investment Director at Capital Group. He has 30 years of investment industry experience and has been with Capital Group for 19 years. Earlier in his career at Capital, he was an investment specialist. He holds both a master’s degree and a bachelor’s degree in engineering from the University of Cambridge. He is an associate member of the Institute of Actuaries. Andy is based in Singapore.

John Lamb is an investment specialist at Capital Group. He has eight years of industry experience and has been with Capital Group for five years. He holds a bachelor's degree in economics and management from the University of Oxford. He also holds the Chartered Financial Analyst® designation. John is based in London. 


過去の実績は将来の成果を保証するものではありません。投資の価値および投資収益は減少することも増加することもあり、当初投資額の一部または全部を失うことがあります。本情報は投資、税務もしくはその他の助言の提供、または証券の売買の勧誘を意図するものではありません。

個人に帰属する記述は、その個人の出版日現在の意見を述べたものであり、必ずしもキャピタル・グループまたはその関連会社の意見を反映したものではありません。特に明記がない限り、すべての情報は記載された日付現在のものです。一部の情報は第三者から取得したものであり、そのため、かかる情報の信頼性については保証いたしません。